Our research builds off the findings of the Human Microbiome Project.
To find out more
Thomas Hitchcock, Ph.D., Founder and CEO, gives an overview of the work being done at Xycrobe Therapeutics.
Immunology in the skin
Courtesy of Springer Nature Publications, and produced with support from Janssen Pharmaceutical Companies of Johnson & Johnson
To find out more, click here.
Probiotic-like XycrobesTM colonize the skin and release skin-healthy
bio-therapeutics to the target tissues
Our XycrobeTM (pronounced ˈzīˌkrōb) technology platform addresses the need of patients with inflammatory skin disease through the development of a library of “good” bacteria strains designed to be used for therapeutic purposes. With our technology, we aim to change the way inflammatory skin disease is treated by 1) addressing bacterial dysbiosis of the skin, 2) addressing immunological or genetic deficiencies found in many affected patients and 3) reducing the incidence of antibiotic-resistant bacterial infections that occur due to overuse of antibiotics and other antimicrobial products.
For more information, please contact us!
Copyright © 2017 Xycrobe Therapeutics, Inc. All rights reserved.